GLP-1 stomach and lung injury lawsuits have been reviewed by the Judicial Panel on Multi-district Litigation (JPML). Upon due consideration, the JPML selected the Eastern District of Pennsylvania (EDPA) as the venue in which Ozempic, Wegovy, Mounjaro and Rybelsus injury claims will be heard by the federal court system.
The Eastern District of Pennsylvania is part of the 3rd Circuit, and appeals are heard by the Third Circuit Court of Appeals.
Consolidation of a multitude of GLP-1 (Ozempic/Wegovy) lawsuits was done pursuant to 28 U.S.C. § 1407. Newly filed GLP-1 cases nationwide are likewise expected to be transferred to the EDPA.
The EDPA was likely chosen partly because more GLP-1/semaglutide lawsuits had been filed in Pennsylvania than in any other state. In addition, the venue is near the New Jersey corporate headquarters of Ozempic, Wegovy & Rybelsus manufacturer Novo Nordisk.
Click here to get started pursuing a GLP-1 injury claim.
Judge Gene E.K. Pratter Presides Over GLP-1 Ozempic Litigation
Judge Gene E.K. Pratter has been selected by the Judicial Panel on Multi-district Litigation to oversee nationwide GLP-1 litigation.
Judge Pratter’s legal journey began with her education at Stanford University and the University of Pennsylvania Law School, followed by a pivotal clerkship with Judge Robert Sprecher on the United States Court of Appeals for the Seventh Circuit. Her dedication to law and justice led to her appointment as a federal judge in 2004 by President George W. Bush. The Hon. Gene E.K. Pratter is known for her fair and insightful approach to complex legal issues, embodying a deep respect for the law throughout her distinguished tenure on the bench.